Alzheimer's - Dementia, Author Interviews, Diabetes, JAMA, Weight Research / 09.04.2025

MedicalResearch.com Interview with: [caption id="attachment_67848" align="alignleft" width="150"]Dr. Catriona Reddin MDFourth year Specialist Registrar in Geriatric Medicine  and an Irish Clinical Academic Training (ICAT) fellow University Hospital Galway, Galway, Ireland Dr. Reddin[/caption] Dr. Catriona Reddin MD Fourth year Specialist Registrar in Geriatric Medicine  and an Irish Clinical Academic Training (ICAT) fellow University Hospital Galway, Galway, Ireland   MedicalResearch.com: What is the background for this study? Response: Dementia is a leading cause of disability globally, which is projected to affect approximately 75 million people by 2030. Diabetes mellitus is a risk factor for dementia, it was unclear if glucose lower therapies reduce the risk of dementia. The research, a systematic review and meta-analysis of 26 clinical trials involving over 160,000 participants, found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—GLP-1Ras—was linked to a significant reduction.
Alzheimer's - Dementia, Author Interviews, Biomarkers / 11.12.2024

MedicalResearch.com Interview with: [caption id="attachment_65442" align="alignleft" width="180"]Alberto J. Espay, MD, MSc, FAANProfessor of Neurology Director and Endowed Chair Gardner Family Center for Parkinson's disease and Movement Disorders University of Cincinnati Academic Health Center Prof. Espay[/caption] Alberto J. Espay, MD, MSc, FAAN Professor of Neurology Director and Endowed Chair Gardner Family Center for Parkinson's disease and Movement Disorders University of Cincinnati Academic Health Center MedicalResearch.com: What is the background for this study? What are the main findings Response:  Because aducanumab, lecanemab, and donanemab were only in a minority of anti-amyloid treatments showing a benefit, I was interested in finding out what makes them special. It turns out that they not only clean the brain from amyloid, like other monoclonal anti-Aβ antibodies, but they also increase Aβ42 in the spinal fluid, which is a measure of the normal protein in the brain. Everyone with Alzheimer’s has low Aβ42 levels because this protein clumps into amyloid plaques. I tested the hypothesis that increasing Aβ42 could explain the cognitive outcomes at least as well as decreasing amyloid, and that’s exactly what we found. This suggests that restoring the normal protein levels, Aβ42, may explain why some anti-amyloid treatments (presumably those that increased those levels the most) come with benefits.
Alzheimer's - Dementia, Author Interviews / 29.08.2024

stethoscope-alzheimers-article

Alzheimer’s disease is the most common condition that leads to a gradual loss of memory and thinking skills. It’s marked by the buildup of plaques and tangles in the brain. It’s one of many different areas where Anavex Life Sciences is focusing its research as part of its mission to develop effective therapeutics for neurodegenerative disorders. In 1984, researchers discovered that a protein called amyloid beta is a key part of the plaques that aggregate in the brain. This led to the theory that Aβ is central to Alzheimer’s, known as the "amyloid cascade hypothesis." Since then, most Alzheimer’s treatments have targeted Aβ. However, many of these treatments have failed in clinical trials, leading to questions about this approach. Aβ is created from a larger protein called amyloid precursor protein through a series of steps involving different enzymes. Normally, APP is processed in a way that prevents the formation of Aβ. However, under certain conditions, the enzymes BACE1 and γ-secretase cut APP in a way that produces Aβ. Once formed, Aβ needs to be cleared from the brain to prevent harmful buildup. Aβ clearance involves several pathways, including enzyme degradation, transport across the blood-brain barrier, and removal through the brain’s fluid drainage systems. The blood-brain barrier is a network of cells that controls what enters and leaves the brain. Specific proteins help move Aβ out of the brain, but for those with Alzheimer’s, these proteins don’t work as well, leading to Aβ accumulation. Genetic studies show that Aβ buildup plays a significant role in the disease. For example, people with Down syndrome, who have an extra copy of the APP gene, often develop Alzheimer’s. Mutations in genes related to APP processing can also cause early-onset Alzheimer’s, while certain mutations can protect against it. Both genetic and lifestyle factors, like diabetes and lack of exercise, can increase Aβ production or hinder its clearance. Despite setbacks, there are promising developments in Aβ-based therapies. Aducanumab, an antibody that targets Aβ, was approved by the FDA for its ability to reduce Aβ plaques in early Alzheimer’s patients. Another antibody, donanemab, has shown even better results in clearing Aβ from the brain. Similarly, lecanemab, which targets soluble forms of Aβ, has been shown to reduce amyloid levels and improve cognitive function. Another drug, Anavex 2-73 (blarcamesine), has shown potential in reducing Alzheimer’s symptoms and brain changes in animal studies and a late stage human trial. Blarcamesine is a formulation of Anavex, a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease and other central nervous system disorders. These advances offer new hope that targeting Aβ could still be a valid approach to treating Alzheimer’s.
Alzheimer's - Dementia, Social Issues / 27.06.2024

Caring for a loved one with dementia at home can be challenging. As a caregiver, it is important to educate yourself on strategies to provide the best care while also taking care of your own wellbeing. Here are some helpful tips for caregivers managing dementia care at home.

Understand the Stages of Dementia

The first step is understanding the different stages of dementia - mild, moderate and severe. Knowing what stage your loved one is in will help you plan care accordingly. In the early stages, maintaining independence may be possible with reminders and the help of home caregivers such as home care services in Greensboro, NC. In the later stages, full-time care is usually required for basic activities like eating, bathing and dressing. Understanding the dementia stage will help you adapt care needs.

caregivers-eldercare_pexels-kampus-7551618Create a Safe, Comfortable Environment

As dementia progresses, people can become disoriented and confused. To limit risks, make sure your home environment is safe and comfortable. Reduce clutter, improve lighting, install handrails and non-slip mats in bathrooms. Lock away medications and toxic products. Consider monitoring systems like motion sensors if the person wanders. Also, ensure favorite belongings and familiar objects are around to provide comfort.
Alzheimer's - Dementia, Author Interviews, JAMA, UC Davis / 25.03.2024

MedicalResearch.com Interview with: [caption id="attachment_61484" align="alignleft" width="150"]Charles DeCarli, MD, FAAN, FAHAVictor and Genevieve Orsi Chair in Alzheimer's Research Distinguished Professor of Neurology Director, Alzheimer's Disease Research Center and Imaging of Dementia and Aging (IDeA) Laboratory Department of Neurology and Center for Neuroscience University of California at Davis Sacramento, CA  95817 Dr. DeCarli[/caption] Charles DeCarli, MD, FAAN, FAHA Victor and Genevieve Orsi Chair in Alzheimer's Research Distinguished Professor of Neurology Director, Alzheimer's Disease Research Center and Imaging of Dementia and Aging (IDeA) Laboratory Department of Neurology and Center for Neuroscience University of California at Davis Sacramento, CA  95817   MedicalResearch.com: What is the background for this study? Response: The overall health of the U.S. population has improved dramatically over the last 100 years, Individuals are also living longer resulting in an increasing percentage of the population at risk for Alzheimer’s disease and related dementias (ADRD).  Recent data from the Framingham Heart study, however, finds that dementia incidence may be declining.  While many factors such as greater educational achievement and medical management of vascular risk factors may explain part of this effect, early life environmental differences also likely contribute.
Alzheimer's - Dementia, Author Interviews, Lifestyle & Health, Nutrition, Vegetarians / 30.05.2023

MedicalResearch.com Interview with: [caption id="attachment_60452" align="alignleft" width="150"]JoAnn E. Manson, MD, DrPH, MACPChief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School Boston, Massachusetts  02215 Dr. Manson[/caption] JoAnn E. Manson, MD, DrPH, MACP Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women's Health Harvard Medical School Boston, Massachusetts  02215   MedicalResearch.com: What is the background for this study?  Any particular types of vitamins, ie with/without iron etc? Response: Preserving memory and cognitive health is a high priority for most mid-life and older adults.  However, few strategies have been rigorously tested in randomized clinical trials and shown to have cognitive benefits. Nutritional approaches hold promise because the brain requires several nutrients for optimal health, and deficiencies in one or more of these nutrients may lead to accelerated memory loss and cognitive decline. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a large-scale nation-wide randomized trial of multivitamins and cocoa flavanols had recently reported that multivitamins slowed global cognitive decline and memory loss (in COSMOS-Mind). The current study was a 2nd parallel trial, a collaboration between Brigham and Women’s Hospital and Columbia University, looking at a web-based assessment of the role of a  standard multivitamin and of cocoa flavanols in slowing age-related memory loss. The report in AJCN is on the multivitamin-cognition findings. The multivitamin tested was Centrum silver for adults (without iron).
Alzheimer's - Dementia / 03.03.2023

Dementia is a condition that affects many older adults aged 65 years and older but is increasingly being diagnosed in much younger people. It is a tragic disease as the personality of the sufferer changes, they struggle to identify close family members, and there is a profoundly sad loss of dignity as the disease progresses. Medical researchers are very active in undertaking experiments to find better ways of early diagnosis and treating patients more effectively. We look at the more recent research in this regard.

Improved Digital Markers

Scientists have found a new method to predict dementia before its onset or while it is still mild. This allows those who are positively identified to make lifestyle changes to stay healthy for longer and to begin preparing for special care when they can no longer look after themselves. The research tests comprised a study of driving behaviors. This was a longitudinal study. It had a 96% accuracy and considered 200 driving elements. Just under 3000 test subjects participated in the study, which took place in five US states. All the participants were still driving their own vehicles as a way of retaining their independence as they entered the older age stages of life, with everyone being between 65 and 79 years of age. Eighty-five percent of this age group were found to still be driving at this stage of life. None had signs of cognitive decline. Follow-up of the participants took place three years after the testing phase. Sixty-one participants had gone on to develop Alzheimer’s disease, some cognitive decline, or other types of dementia. The researchers compared their results against two other popular methods (logistic regression and random forests) of predicting dementia and found that their test had a 6-10% greater accuracy than the rest. Two aspects of driving that were especially useful for predicting future dementia were how many times drivers braked hard with 0.4 g or greater deceleration and the ratio of right and left turns. Regarding the latter, older people found it less risky to turn right rather than left. Early warning of possible dementia later in life is essential to preparing for increasing levels of care, from overnight, to 24/7. Check out this guide if you want to know more about what is overnight care. Many dementia patients with mild impairment may start with this form of assistance. A bit of help when needed can allow the person to store their energy for greater independence in intimate activities like bathing.
Aging, Alzheimer's - Dementia, Author Interviews, Hearing Loss, JAMA, Johns Hopkins / 10.01.2023

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle,   MedicalResearch.com Interview with: [caption id="attachment_59905" align="alignleft" width="200"]Alison R. Huang, PhD MPH Senior Research Associate Cochlear Center for Hearing & Public Health Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Dr. Huang[/caption] Alison R. Huang, PhD MPH Senior Research Associate Cochlear Center for Hearing & Public Health Department of Epidemiology Johns Hopkins Bloomberg School of Public Health MedicalResearch.com: What is the background for this study? What are the main findings? Response: Hearing loss is a critical public health issue affecting two-thirds of older adults over 70 years old. There is growing understanding of a strong link between hearing loss and dementia, which impacts millions of Americans. Our main findings are that in a nationally representative sample of older adults in the United States from the National Health and Aging Trends Study, every 10 decibel increase in hearing loss was associated with 16% greater prevalence of dementia, such that prevalence of dementia in older adults with moderate or greater hearing loss was 61% higher than prevalence in those with normal hearing. We also found that in older adults with moderate or greater hearing loss, hearing aid use was associated with a 32% lower prevalence of dementia.
Alzheimer's - Dementia, Author Interviews, Race/Ethnic Diversity, UCSF / 20.04.2022

MedicalResearch.com Interview with: [caption id="attachment_59076" align="alignleft" width="150"]Erica Kornblith, PhD Assistant Professor, Psychiatry UCSF Weill Institute for Neurosciences Dr. Kornblith[/caption] Erica Kornblith, PhD Assistant Professor, Psychiatry UCSF Weill Institute for Neurosciences MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: As the population of the United States grows more diverse and dementia is a serious public health concern, we hoped to understand whether differences in dementia risk exist based on race or ethnicity.  Older studies have shown that Black and Hispanic folks have higher risk of dementia, perhaps due to medical risk factors, diagnostic bias, lack of equal access to health care and education, or the health effects of racism, among other factors.  However, these older studies have been small or limited geographically or by only studying a few race and ethnicity groups. Our study used a nationwide sample of almost two million older Veterans who all had access to care through the Veterans Health Administration (VHA), and we examined 5 race or ethnicity groups: American Indians or Alaska Natives, Asians, Blacks, Hispanics, and Whites. Our results show that dementia risk is higher for Black and Hispanic Veterans compared to white Veterans, even when education and medical factors are considered.
Aging, Author Interviews, Geriatrics, PLoS, Social Issues / 17.03.2022

MedicalResearch.com Interview with: [caption id="attachment_58908" align="alignleft" width="127"]Dr Holly Bennett PhD Research Associate Population Health Sciences Institute Campus for Ageing and Vitality Newcastle upon Tyne Dr. Bennett[/caption] Dr. Holly Bennett PhD Research Associate Population Health Sciences Institute Campus for Ageing and Vitality Newcastle upon Tyne MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Life expectancy has been increasing over time and we want to ensure these are years in good health rather than increasing years in poor health. There has mainly been good news for those living with long term health conditions. With better treatment, prevention and care, the proportion of remaining years lived disability-free has increased for more recent generations.
Alzheimer's - Dementia, Author Interviews, JAMA, Ophthalmology / 06.12.2021

MedicalResearch.com Interview with: [caption id="attachment_58453" align="alignleft" width="150"]Cecilia S. Lee, MD, MS Associate Professor,Director, Clinical Research Department of Ophthalmology Harborview Medical Center University of Washington Seattle, WA Dr. Lee[/caption] Cecilia S. Lee, MD, MS Associate Professor,Director, Clinical Research Department of Ophthalmology Harborview Medical Center University of Washington Seattle, WA MedicalResearch.com: What is the background for this study? Response: Cataract is a natural aging process of the eye and affects the majority of older adults who are at risk for dementia. Sensory loss, including vision and hearing, is of interest to the research community as a possible risk factor for dementia, and also as a potential point of intervention. Because cataract surgery improves visual function, we hypothesized that older people who undergo cataract surgery may have a decreased risk of developing Alzheimer disease and dementia. We used the longitudinal data from an ongoing, prospective, community based cohort, Adult Changes in Thought (ACT) study. The ACT study includes over 5000 participants to date who are dementia free at recruitment and followed until they develop Alzheimer disease or dementia. We had access to their extensive medical history including comprehensive ophthalmology visit data. We investigated whether cataract surgery was associated with a decreased risk of developing Alzheimer disease and dementia. 
Abuse and Neglect, BMJ, Cognitive Issues, Occupational Health / 24.08.2021

MedicalResearch.com Interview with: [caption id="attachment_57967" align="alignleft" width="80"]Prof-Mika-Kivimaki Prof Kivimaki[/caption] Prof Mika Kivimaki PhD Director, Whitehall II Study Dept. of Epidemiology University College London MedicalResearch.com: What is the background for this study? Response: The Lancet 2020 Commission on Dementia Prevention, which is the most comprehensive and up-to-date review on the evidence in this field, did not list cognitive stimulation in adulthood as a protective factor against dementia. This was because trials results are inconsistent and observational studies suggest that leisure time cognitive activity does not reduce risk of dementia. However, it was unclear whether the reason for modest findings is that the decrease in brain plasticity with age prevents cognitive activities across adult life from conferring protection against dementia, or, in the case of interventions, that the cognitive stimulation studied has not been intensive or engaging enough to preserve cognitive function. To address this question, we decided to focus on cognitive stimulation at work rather than leisure time cognitive activity or cognitive interventions. We thought that this approach would allow us to detect an effect, if there is one, because exposure to cognitive stimulation at work typically lasts considerably longer than cognitively stimulating hobbies or cognitive interventions. We contacted 13 cohort studies in Europe which had data on cognitive stimulation at work. Seven had also a dementia follow-up and were selected to our analyses, a total of 107 896 dementia-free participants from the UK, France, Sweden and Finland. Follow-up of incident dementia varied between 13.7 to 30.1 years depending on the cohort. 1143 people developed dementia during this follow-up.
Alzheimer's - Dementia, Author Interviews, Dermatology / 15.08.2021

MedicalResearch.com Interview with: [caption id="attachment_57957" align="alignleft" width="200"]Annakaisa Haapasalo Dr. Haapasalo[/caption] Annakaisa Haapasalo, PhD Adjunct Professor Research Director (Associate Professor A.I. Virtanen Institute for Molecular Sciences Molecular Neurodegeneration University of Eastern Finland | UEF |   MedicalResearch.com: What is the background for this study? At what age might these changes be present? Response: Our research team is interested in understanding the underlying disease mechanisms and developing biomarkers for frontotemporal dementia (FTD). FTD is the second most common cause of dementia in the working age population. Presently, no efficient therapies exist for FTD, it is challenging to diagnose, and the disease mechanisms of different types of FTD remain largely unclear. We are especially interested in FTD associated with the C9orf72 repeat expansion because it is the most common genetic cause of frontotemporal dementia and exceptionally prevalent in Finnish FTD patients. Many current studies of FTD and C9orf72 repeat expansion have largely concentrated on examining neurons, as these are the principle CNS cells that are affected in neurodegeneration. Neurons are also one of our key research interests, but obtaining neurons directly from living patients is difficult in many ways. Therefore, we became interested in exploring the FTD patient skin fibroblasts with the idea in mind that they might represent more easily accessible patient-derived cells than neurons for trying to decipher disease mechanisms of FTD. Moreover, we were interested in finding out if these cells show any specific alterations or deficiencies that could be utilized later on in biomarker studies or testing drug effects. 
Alzheimer's - Dementia, Author Interviews, Cognitive Issues, Obstructive Sleep Apnea, Pulmonary Disease, University of Michigan / 16.04.2021

MedicalResearch.com Interview with: [caption id="attachment_57162" align="alignleft" width="125"]Galit Levi Dunietz  MPH, PhD Pronouns: she, her Assistant Professor University of Michigan, Medical School Department of Neurology, Division of Sleep Medicine School of Public Health Department of Nutritional Sciences Ann Arbor, MI 48109-5845 Dr. Dunietz[/caption] Galit Levi Dunietz  MPH, PhD Assistant Professor
[caption id="attachment_57164" align="alignleft" width="108"]Tiffany Braley, MD, MS Clinical Associate Professor Dr. Braley[/caption]

Tiffany Braley, MD, MS Associate Professor

University of Michigan, Medical School Department of Neurology Department of Nutritional Sciences Ann Arbor, MI 48109-5845 MedicalResearch.com: What is the background for this study? Response: Dementia is a public health crisis that affects more than 6 million Americans.  As no treatments to effectively reverse dementia are currently available, interest has shifted toward modifiable risk factors for dementia, which may offer a critical window for prevention or intervention. Recent research suggests that obstructive sleep apnea (OSA) is a common, yet undiagnosed, risk factor for cognition impairment in older adults. However, few studies have examined whether treatment of OSA with positive airway pressure (PAP) therapy could protect those with OSA against developing dementia, says principal investigator, Dr. Tiffany Braley, MD, MS, Associate Professor of Neurology from the University of Michigan. To address this gap, Dr. Braley and Dr. Galit Levi Dunietz, PhD, MPH, Assistant Professor and sleep epidemiologist, examined associations between PAP therapy use and 3-year incidence of Alzheimer’s disease, mild cognitive impairment (MCI), or other forms of dementia (DNOS, “dementia not otherwise specified”).
Alzheimer's - Dementia, Author Interviews, Lipids, Mental Health Research, Microbiome / 18.11.2020

MedicalResearch.com Interview with: [caption id="attachment_55988" align="alignleft" width="200"]Moira Marizzoni, PhD Researcher, Fatebenefratelli Center in Brescia  Dr. Marizzoni[/caption] Moira Marizzoni, PhD Researcher, Fatebenefratelli Center in Brescia  MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease is the most common cause of dementia. Still incurable, it directly affects nearly one million people in Europe, and indirectly millions of family members as well as society as a whole. The gut microbiota could play a role in brain diseases including Alzheimer’s disease. Some gut bacteria components or products can reach the brain via the blood and might promote brain amyloidosis (one of the main pathological features in Alzheimer’s disease).   MedicalResearch.com: What are the main findings?  Response: This study evaluated a cohort of 89 people between 65 and 85 years of age composed of subjects suffering from Alzheimer’s disease or other neurodegenerative diseases causing similar memory problems, and of subjects with no memory problems. The study revealed that elevated levels of microbiota-products with known pro-inflammatory properties (i.e. lipopolysaccharides and the short chain fatty acids acetate and valerate) were associated with greater cerebral amyloid pathology while elevated levels of those with anti-inflammatory properties (i.e. the short chain fatty acid butyrate) were associated with lower amyloid pathology.
Alzheimer's - Dementia, Author Interviews, Blood Pressure - Hypertension, Neurology, UCSF / 10.08.2020

MedicalResearch.com Interview with: Laure Rouch, PharmD PhD Department of Psychiatry Dr. Kristine Yaffe, MD (Senior Author) Departments of Psychiatry, Neurology, and Epidemiology University of California San Francisco, San Francisco VA Medical Center, San Francisco, CA, USA MedicalResearch.com: What is the background for this study? Response: Worldwide, around 50 million people have dementia and this number is set to triple by 2050. Prevention of dementia and identification of potentially modifiable risk factors are, therefore, critically important. Postural changes in blood pressure increase with advancing age and affect 20% to 30% of older adults. Yet it has not been explored deeply how orthostatic hypotension and blood pressure postural changes variability over time are associated with dementia risk. As multiple pharmacologic and nonpharmacologic interventions may improve orthostatic symptoms, this question has major public health implications.
Alzheimer's - Dementia, Author Interviews, Cognitive Issues, JAMA, Lipids / 14.07.2020

MedicalResearch.com Interview with: [caption id="attachment_51654" align="alignleft" width="133"]Manja Koch Dr. oec. troph. (Ph.D. equivalent) Research Associate Department of Nutrition Harvard T.H. Chan School of Public Health Dr. Koch[/caption] Manja Koch, Ph.D., Research Associate Department of Nutrition Harvard T.H. Chan School of Public Health [caption id="attachment_51694" align="alignleft" width="150"]Majken K. Jensen, PhD Associate Professor of Nutrition Harvard T.H. Chan School of Public Health Dr. Jensen[/caption] Majken K. Jensen, Ph.D. Adjunct Professor of Nutrition Harvard T.H. Chan School of Public Health & Professor in the Department of Public Health University of Copenhagen, Copenhagen, Denmark     MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease and other dementias are highly prevalent conditions. According to the Alzheimer’s Association, 50 million people are currently living with Alzheimer’s disease or other dementias worldwide. Lower apolipoprotein E in plasma is a risk factor for dementia, but the underlying biological mechanisms are not fully understood. Thus, we investigated the role of apolipoprotein E overall and in lipoproteins with distinct metabolic functions in relation to cognitive function and dementia risk..
Author Interviews / 01.07.2020

MedicalResearch.com Interview with: [caption id="attachment_54754" align="alignleft" width="200"]Ruiyuan Zhang, MD, MS Department of Epidemiology and Biostatistics University of Georgia College of Public Health Athens, Georgia Dr. Zhang[/caption] Ruiyuan Zhang, MD, MS Department of Epidemiology and Biostatistics University of Georgia College of Public Health Athens, Georgia MedicalResearch.com: What is the background for this study? Response: Although there are several studies that focused on the effect of alcohol drinking on cognitive function, their findings were still mixed. So we want to use some new analysis techniques on this topic to see if we can have new findings. MedicalResearch.com: What are the main findings? Response: The main finding of our study is that low-to-moderate alcohol drinking is associated with better cognitive function outcomes.
Alzheimer's - Dementia, Author Interviews, Hearing Loss / 28.02.2020

MedicalResearch.com Interview with: [caption id="attachment_53358" align="alignleft" width="160"]Julia Sarant, PhD  Associate Professor Department of Audiology and Speech Pathology Faculty of Medicine, Dentistry and Health Sciences Melbourne School of Health Sciences Dr. Sarant[/caption] Julia Sarant, PhD Associate Professor Department of Audiology and Speech Pathology Faculty of Medicine, Dentistry and Health Sciences Melbourne School of Health Sciences MedicalResearch.com: What is the background for this study? Response: Dementia is a rapidly growing global problem. Hearing loss has been identified by the Lancet Commissions as a modifiable risk factor for dementia. There is no treatment for dementia. This study investigated the effect of hearing aid use on cognition over time in older adults, objectively assessing hearing loss treatment, compliance and benefits while controlling for the effects of other known risk factors for dementia. 
Author Interviews, Cognitive Issues / 24.02.2020

MedicalResearch.com Interview with: [caption id="attachment_53278" align="alignleft" width="200"]Terese Sara Høj Jørgensen PhD Assistant Professor Faculty of Health and Medical Sciences University of Copenhagen Dr. Jørgense[/caption] Terese Sara Høj Jørgensen PhD Assistant Professor Faculty of Health and Medical Sciences University of Copenhagen MedicalResearch.com: What is the background for this study? Response: Dementia may develop as a result of both genetics and environmental exposures operating throughout the life course, and the risk of dementia may already be established early in life. Body height has a strong genetic component and is at the same time influenced by environmental factors early in life. Body height is an expression of growth early in life and a taller body height could express that the body has had an optimal development. At the same time, a shorter body height could be an indicator of harmful exposures early in life. A few smaller studies have identified a link between body height and dementia. However, rather than being a risk factor of dementia in itself, body height is likely an indicator of harmful exposures early in life and hereby linked to dementia. Body growth could furthermore be linked to dementia as an indicator of brain and cognitive reserve. Thus, to understand the relationship between body height and dementia, large scale high-quality longitudinal studies exploring the impact of early environmental factors and genetics to explain the link between body height and dementia were needed prior to this study.
Alzheimer's - Dementia, Author Interviews, Technology / 08.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52700" align="alignleft" width="200"]Ao.Univ.-Prof. Priv.-Doz. Dr.med.univ. Roland Beisteiner. Department of Neurology Laboratory for Functional Brain Diagnostics and Therapy High Field MR Center, Medical University of Vienna Vienna, Austria Dr. Beisteiner[/caption] Dr.med.univ. Roland Beisteiner Department of Neurology Laboratory for Functional Brain Diagnostics and Therapy High Field MR Center, Medical University of Vienna Vienna, Austria MedicalResearch.com: What is the background for this study? What are the main findings? Response: The background is the development of a new brain therapy which allows to support brain regeneration by activation of neurons with pulsed ultrasound. Main findings are that Alzheimer's patients improve their memory up to 3 months.
Alzheimer's - Dementia, Author Interviews, Environmental Risks / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52554" align="alignleft" width="200"]Professor Esme Fuller-Thomson, PhD Director of the Institute for Life Course & Aging, Factor-Inwentash Faculty of Social Work Cross-appointed to the Faculty of Medicine University of Toronto Canada Dr. Fuller-Thomson[/caption] Professor Esme Fuller-Thomson, PhD Director of the Institute for Life Course & Aging, Factor-Inwentash Faculty of Social Work Cross-appointed to the Faculty of Medicine University of Toronto Canada MedicalResearch.com: What is the background for this study? Response: Several studies from the US, Canada, and Europe suggest a promising downward trend in the incidence and prevalence of dementia. Important risk factors for dementia, such as mid-life obesity and mid-life diabetes, have been increasing rapidly, so the decline in dementia incidence is particularly perplexing.
Alzheimer's - Dementia, Author Interviews, Mental Health Research / 08.10.2019

MedicalResearch.com Interview with: [caption id="attachment_51779" align="alignleft" width="200"]Marjaana Koponen, PhD Postdoctoral Researcher Kuopio Research Centre of Geriatric Care School of Pharmacy University of Eastern Finland Dr. Koponen[/caption] Marjaana Koponen, PhD Postdoctoral Researcher Kuopio Research Centre of Geriatric Care School of Pharmacy University of Eastern Finland MedicalResearch.com: What is the background for this study? What are the main findings? Response: It is known that antipsychotics are commonly used in the treatment of behavioral and psychological symptoms of dementia, although their use has been linked to serious adverse events. In this study, we found that community dwellers with Alzheimer’s disease who initiated antipsychotic use accumulated more hospital days than non-initiators. This may partially reflect adverse effects and events of antipsychotic use. On the other hand, antipsychotic users accumulated more hospital days due to dementia, mental and behavioral disorders and their caregivers’ days off. Thus, another reason for a higher accumulation of hospital days is care burden and the difficulties in treating the most severe behavioral and psychological symptoms of dementia.
Alzheimer's - Dementia, Author Interviews, Cognitive Issues, Duke, Neurology / 24.09.2019

MedicalResearch.com Interview with: Juan Helen Zhou, PhD, on behalf of the co-authors Associate Professor and Principal Investigator Neuroscience and Behavioural Disorders (NBD) Programme Duke-NUS Medical School, SingaporeJuan Helen Zhou, PhD, on behalf of the co-authors Associate Professor and Principal Investigator Neuroscience and Behavioural Disorders (NBD) Programme Duke-NUS Medical School, Singapore  MedicalResearch.com: What is the background for this study? Response: Alzheimer’s disease and cerebrovascular disease are among the leading disorders affecting the elderly, with up to 50 per cent of dementia patients showing co-occurrence of both disorders. It is therefore of great interest to understand the influence of co-occurring Alzheimer’s disease and cerebrovascular disease pathologies on brain changes, and examine if such changes are able to track early differential disease progression. Past cross-sectional studies have suggested that Alzheimer's disease and cerebrovascular disease pathologies contribute independently to brain functional and structural changes, and cognitive decline. Our study sought to demonstrate the independent contributions of both pathologies to brain functional networks in a longitudinal cohort of mild cognitive impairment patients, often regarded as early stage of the disease.
Alzheimer's - Dementia, Author Interviews, JAMA, Mental Health Research, Sleep Disorders / 23.08.2019

MedicalResearch.com Interview with: Chenlu Gao, MA Graduate Student Department of Psychology and Neuroscience Baylor University Michael Scullin, PhD Assistant Professor Department of Psychology and Neuroscience Baylor University  MedicalResearch.com: What is the background for this study? Response: According to the World Alzheimer Report, dementia affects 50 million adults worldwide, and this number is expected to approach 131 million by 2050. Dementia patients often require assistance with daily activities from caregivers. The Alzheimer’s Association reported that, in the United States, 16 million caregivers spend on average 21.9 hours per week providing care for patients with dementia. Being a caregiver is stressful, which not only challenges emotional, cognitive, and physical health, but is also associated with shorter and poorer sleep at night. If a caregiver cannot obtain restorative sleep at night, their quality of life and their abilities to perform the caregiving role can be compromised. For example, sleep loss may jeopardize caregivers’ memory, causing them to forget medications or medical appointments for the patients. Sleep loss can also impair immune functions, causing the caregivers to suffer from illnesses. In the long-term, sleep loss is associated with cortical thinning and accumulation of beta-amyloid and tau, which increase the risks of dementia. Undoubtedly, there is a need to systematically study whether caregivers sleep less or worse during the night and whether we can improve their sleep quality through low-cost behavioral interventions. To answer these questions, we systematically reviewed and meta-analyzed 35 studies with data from 3,268 caregivers of dementia patients.    
Author Interviews, Cognitive Issues, End of Life Care, Gender Differences, JAMA / 16.08.2019

MedicalResearch.com Interview with: [caption id="attachment_50851" align="alignleft" width="142"]Dr. Nathan Stall, MD Geriatrician and Research fellow Women’s College Research Institute Dr. Stall[/caption] Dr. Nathan Stall, MD Geriatrician and Research fellow Women’s College Research Institute   [caption id="attachment_50852" align="alignleft" width="133"]Dr. Paula Rochon, MD, MPH, FRCPC Periatrician and Vice-President of Research Women’s College Hospital Dr. Rochon[/caption]     Dr. Paula Rochon, MD, MPH, FRCPC Periatrician and Vice-President of Research Women’s College Hospital     MedicalResearch.com: What is the background for this study? Response: The advanced stages of the dementia are characterized by profound memory impairment, an inability to recognize family, minimal verbal communication, loss of ambulatory abilities, and an inability to perform basic activities of daily living. Nursing homes become a common site of care for people living with advanced dementia, who have a median survival of 1.3 years. In the advanced stages of the disease, the focus of care should generally be on maximizing quality of life. Our study examined the frequency and sex-based differences in burdensome interventions received by nursing home residents with advanced dementia at the very end of life. Burdensome interventions include a variety of treatment and procedures that are often avoidable, may not improve comfort, and are frequently distressing to residents and their families. We found that in the last 30 days of life, nearly one in 10 nursing home residents visited an emergency department, more than one in five were hospitalized, and one in seven died in an acute care setting. In addition, almost one in 10 residents received life-threatening critical care; more than one in four were physically restrained; and more than one in three received antibiotics.
Author Interviews, Cognitive Issues, Nutrition, Red Meat / 08.08.2019

MedicalResearch.com Interview with: [caption id="attachment_50601" align="alignleft" width="200"]Jyrki Virtanen, PhD Assistant professor of nutritional epidemiology (tenure track) University of Eastern Finland Institute of Public Health and Clinical Nutrition Kuopio, Finland Dr. Virtanen[/caption] Jyrki Virtanen, PhD Assistant professor of nutritional epidemiology University of Eastern Finland Institute of Public Health and Clinical Nutrition Kuopio, Finland MedicalResearch.com: What is the background for this study? What are the main findings?  Response: We have previously found in this same eastern Finnish male study population that higher egg intake was associated with lower risk of developing dementia and with better performance in tests assessing cognitive capacity. Eggs are a major source of choline, especially phosphatidylcholine, and choline (which is an essential nutrient) is necessary for the formation of acetylcholine, which is a neurotransmitter. Earlier studies have linked choline intake with better cognitive processing but there was no information whether choline intake would also be associated with lower risk of developing dementia. So the purpose of our current study was to investigate whether higher choline intake would associate with better cognitive performance and with lower risk of dementia, which would support our previous findings with egg intake. And in the current study we did find that especially higher phosphatidylcholine intake was associated with a lower risk of developing dementia and also with better performance in tests measuring memory and linguistic abilities of the men in the study.
ALS, Alzheimer's - Dementia, Author Interviews, Biomarkers, JAMA, Multiple Sclerosis / 27.06.2019

MedicalResearch.com Interview with: [caption id="attachment_50018" align="alignleft" width="200"]Charlotte E. Teunissen, Prof. Teunissen[/caption] Charlotte E. Teunissen, PhD Neurochemistry Laboratory, Department of Clinical Chemistry VU University Medical Centre, Neuroscience Campus Amsterdam Amsterdam, the Netherlands MedicalResearch.com: What is the background for this study? What are the main findings? Response: Several reports have shown increased in NfL in various neurological disorders, separately. We wanted to know how the levels are in these disorders relative to each other. Moreover, some reports showed absence of age effects in Multiple Sclerosis (MS) patients, which is normally present in controls. So, we thought that it would be good to study age effects in a large group of controls, and if these effects are absent in other diseases, similarly as in MS.
Alzheimer's - Dementia, Author Interviews, Sleep Disorders / 21.06.2019

sleep-alzheimers-dementia-insomniaSleep patterns can predict the increase of Alzheimer’s pathology proteins tau and β-amyloid later in life, according to a June 2019 study published in the Journal of Neuroscience. The findings shed hope on earlier diagnosis of Alzheimer’s and the adoption of preventive measures earlier in life. Researchers found a decrease in sleep spindle synchronization, which is linked to higher tau levels. Reduced amplitude of slow wave activity, meanwhile, is closely related to higher β-amyloid levels. In younger people, both slow oscillations and sleep spindles are synchronized. This changes as people grow older, with less coordination between the two being visible. The researchers also noted that subjects who slept less had a higher chance of having Alzheimer’s proteins when they were older. The findings show that both reduced sleep quantity and quality can serve as important warnings of the onset of Alzheimer’s.